Transcript Diapositiva 1

Castrate-Sensitive Metastatic PC
OS by extent of metastatic disease at start of ADT
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
Metastatic Hormone-Sensitive
Prostate Cancer: Standards in 2014
1. Continuous androgen deprivation therapy (ADT) is the
standard based on optimal survival outcomes
2. Patients with new high-volume M1 prostate cancer should
be offered combination ADT + Docetaxel
3. Patients should be offered access to clinical trials